ADVAIR DISKUS is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in adults and children aged 4 years and older. ADVAIR DISKUS contains salmeterol, the same medicine found in SEREVENT DISKUS (salmeterol xinafoate inhalation powder).
ADVAIR DISKUS 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic …
ADVAIR for Asthma and ADVAIR DISKUS 250/50 for COPD | ADVAIR.com
Learn about ADVAIR for the treatment of asthma and ADVAIR DISKUS 250/50 for COPD, including risks and side effects.
FLOVENT DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. FLOVENT DISKUS should be administered by the orally inhaled route in patients aged 4 years and older.
ADVAIR DISKUS INH PWDR 250/50MCG 60 ACTN | Pharma | Products - gsk …
ADVAIR DISKUS INH PWDR 250/50MCG 60 ACTN (fluticasone propionate-salmeterol 250/50 mcg inh pwdr 60D)
ADVAIR/ADVAIR DISKUS (fluticasone propionate/salmeterol) is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for the maintenance treatment of asthma, in patients with reversible obstructive airways disease.
Products | Respiratory | GSK US Medical Affairs
Find GSK US respiratory product information: Prescribing Information, storage and handling, and more.
2023年11月27日 · VENTOLIN DISKUS inhalation powder is a disposable blue-coloured plastic inhaler device containing a foil strip with 60 blisters. Each blister contains 200 mcg of the active ingredient salbutamol (as the sulfate salt).
GSK’s Advair® Diskus® achieves primary endpoint in LABA …
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced results from the paediatric ‘LABA’ (long acting beta 2 -agonist) safety study. VESTRI (SAS115358) compared Advair ® Diskus ® (FSC), a combination of the LABA, salmeterol, and the inhaled corticosteroid (ICS), fluticasone propionate (FP), to FP monotherapy in children aged 4 – 11 years.
SEREVENT DISKUS (salmeterol xinafoate) is indicated for the treatment of asthma only as add-on therapy to an inhaled corticosteroid; a long-term asthma control medication; in patients 4 years of age and older with reversible obstructive airway …